Prescribing overview
An equine injectable sedative and analgesic with U.S. adult-horse conditions of use; current safety details below are explicitly from Great Britain labeling.
The current U.S. regulation describes adult-horse procedural sedation/analgesia and preanesthesia. This entry supplements that narrow regulatory scope with the September 2026 Great Britain SPC, clearly identified so that its warnings are not mistaken for current U.S. product labeling.
Key prescribing checks
- Review the source-specific safety card and monitoring plan before use.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Horses
U.S. labeled/regulatory equine use; see exact scopeSedation/analgesia for handling, examinations, minor procedures and preanesthesia in adult horses
U.S. eCFR indication; verify an available lawful product and its actual labeling before use.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Great Britain manufacturer information describes central alpha-2 receptor-mediated sedation and analgesia.
Absorption, distribution, metabolism and elimination
Manufacturer information describes predominantly urinary elimination and inactive metabolites; these data do not establish a patient-specific redosing interval.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Sedivet
Great Britain Sedivet SPC safety summary; separate U.S. regulatory indication noted.
Contraindications · when not to use
- Great Britain SPC: do not use in the last month of pregnancy.
Precautions & monitoring
- Safety statements in this card are Great Britain product information, not a substituted U.S. insert.
- U.S. regulation excludes horses intended for human consumption.
This is a selected source summary, not exhaustive prescribing guidance.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
The Great Britain SPC lists bradycardia, heart block, hypotension, ataxia, sweating and hypersensitivity; cardiovascular disease requires particular care.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No numerical regimen or automatic calculation. Confirm jurisdiction, actual product availability and current local prescribing information.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Sedivet
Great Britain Sedivet SPC safety summary; separate U.S. regulatory indication noted.
- Great Britain SPC advises against IV potentiated sulfonamides during sedation because potentially fatal arrhythmias have been reported with this class.
- Other psychoactive drugs can potentiate sedation and reduce anesthetic requirements.
Monitoring
Assess cardiovascular status, respiration, sedation depth and safe recovery; defensive kicking can persist despite apparent sedation.
Client counseling
Use a quiet recovery environment. Accidental human self-injection needs immediate medical assessment; do not drive.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Follow the actual product label; Great Britain SPC specifies a first-opening use limit and prohibits mixing without compatibility data.
Brands, formulations & ingredient identity
Active ingredients
Romifidine hydrochloride
Other searchable names: Sedivet
Sedivet is a verified romifidine brand. U.S. approval history does not confirm current U.S. commercial availability or the equivalence of compounded products.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Sedivet
- Formulation
- Romifidine hydrochloride injection
- Label / product scope
- Horses
Safety scope: Great Britain SPC. U.S. availability not confirmed.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
